AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28339460 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1112
Study 26475792 — intervention group
Group type: EXPERIMENTAL
Intervention: CRYO catheter
Number of subjects: 100
Study 26475792 — intervention group
Group type: COMPARATOR
Intervention: VGLA catheter
Number of subjects: 100
Study 23430672 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined formulation of antioxidants and long-chain EPUFAs (DEDG+S)
Number of subjects: 0
Study 23430672 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study 23430672 — intervention group
Group type: EXPERIMENTAL
Intervention: DEDG-NS (no supplementation)
Number of subjects: 0
Study 23430672 — intervention group
Group type: EXPERIMENTAL
Intervention: CG-NS (no supplementation)
Number of subjects: 0
Study 21934576 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16-ELISA at manufacturer cut point
Number of subjects: 0
Study 21934576 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16-ELISA at optimal cut point
Number of subjects: 0
Study 21934576 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV18-ELISA at manufacturer cut point
Number of subjects: 0
Study 21934576 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV18-ELISA at optimal cut point
Number of subjects: 0
Study 17616556 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once a day
Number of subjects: 458
Study 17616556 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice a day
Number of subjects: 458
Study 17616556 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg twice a day
Number of subjects: 458
Study 16423738 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of a list of semantic associates with omission of one non‐presented word's associates in the second presentation.
Number of subjects: 0
Study 16423738 — intervention group
Group type: COMPARATOR
Intervention: Presentation of a list of semantic associates without omission (control group).
Number of subjects: 0
Study 14978780 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 6787
Study 14978780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6787
Study 10940060 — intervention group
Group type: EXPERIMENTAL
Intervention: Versapulse QS Nd:YAG 532 nm laser
Number of subjects: 34
Study 10940060 — intervention group
Group type: EXPERIMENTAL
Intervention: Versapulse long-pulsed Nd:YAG 532 nm laser
Number of subjects: 34
Study 10940060 — intervention group
Group type: COMPARATOR
Intervention: Conventional QS Nd:YAG 532 nm laser
Number of subjects: 34
Study 9136264 — intervention group
Group type: EXPERIMENTAL
Intervention: Central foveal scotoma
Number of subjects: 0
Study 9136264 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafoveal scotoma
Number of subjects: 0
Study 9136264 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no scotoma)
Number of subjects: 0
Study 8336190 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 294
Study 8336190 — intervention group
Group type: COMPARATOR
Intervention: Misonidazole
Number of subjects: 294
Study 3773581 — intervention group
Group type: EXPERIMENTAL
Intervention: Group practice model
Number of subjects: 302
Study 3773581 — intervention group
Group type: COMPARATOR
Intervention: Traditional clinic
Number of subjects: 302
Study 31215676 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin tablets (875 mg)
Number of subjects: 20
Study 31215676 — intervention group
Group type: COMPARATOR
Intervention: Oral amoxicillin suspension (800 mg)
Number of subjects: 20
Study 28532232 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed hydro-alcoholic solution of P. alkekengi, E. amoenum and V. odorata extracts (1.5, 1 and 1.5% respectively)
Number of subjects: 86
Study 28532232 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 86
Study 25528311 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill in the evening (aspirin 75 mg, simvastatin 40 mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)
Number of subjects: 78
Study 25528311 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill in the morning
Number of subjects: 78
Study 25528311 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill in the evening
Number of subjects: 78
Study 25528311 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill
Number of subjects: 78
Study 22538325 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 37
Study 22538325 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 37
Study 21617253 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfracturing
Number of subjects: 42
Study 21617253 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation
Number of subjects: 42
Study 21617253 — intervention group
Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 42
Study 18357530 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC)
Number of subjects: 125
Study 18357530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 16946176 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium augmentation (up to 900 mg/day; N=69)
Number of subjects: 142
Study 16946176 — intervention group
Group type: EXPERIMENTAL
Intervention: T(3) augmentation (up to 50 mug/day; N=73)
Number of subjects: 142
Study 12580666 — intervention group
Group type: EXPERIMENTAL
Intervention: 3L‐1U group (n = 8) - trained 3 sets in leg exercises and 1 set in upper‐body exercises
Number of subjects: 18
Study 12580666 — intervention group
Group type: EXPERIMENTAL
Intervention: 1L‐3U group (n = 10) - trained 1 set in leg exercises and 3 sets in upper‐body exercises
Number of subjects: 18
Study 12580666 — intervention group
Group type: EXPERIMENTAL
Intervention: 3L‐1U group
Number of subjects: 18
Study 12580666 — intervention group
Group type: EXPERIMENTAL
Intervention: 1L‐3U group
Number of subjects: 18
Study 11420323 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy (6 hours continuous)
Number of subjects: 202
Study 11420323 — intervention group
Group type: COMPARATOR
Intervention: Control (6 hours without phototherapy)
Number of subjects: 202
Study 9285026 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP vaccine
Number of subjects: 22505
Study 9285026 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated children
Number of subjects: 22505
Study 8325280 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 139
Study 3548793 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric 0.5% bupivacaine (in 8% glucose)
Number of subjects: 40
Study 3548793 — intervention group
Group type: COMPARATOR
Intervention: Plain 0.5% bupivacaine (glucose-free)
Number of subjects: 40
Study 3548793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study 31820605 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion combined with Wenyang Lishui formula
Number of subjects: 60
Study 31820605 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of paclitaxel liposome and cisplatin
Number of subjects: 60
Study 28213595 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Cycle Therapy (SCT) (5 days on: 2 days off)
Number of subjects: 49
Study 28213595 — intervention group
Group type: COMPARATOR
Intervention: Continuous efavirenz (EFV)-based antiretroviral therapy (CT)
Number of subjects: 49
Study 26761970 — intervention group
Group type: EXPERIMENTAL
Intervention: Meldonium (mildronate) during 12 weeks
Number of subjects: 67
Study 22872429 — intervention group
Group type: EXPERIMENTAL
Intervention: TransInguinal PrePeritoneal (TIPP) repair
Number of subjects: 302
Study 22872429 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein technique
Number of subjects: 302
Study 21247651 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% solution of tannin rich plant extracts (AS-21) applied topically for 6 weeks
Number of subjects: 93
Study 21247651 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glycerol and honey) applied topically for 6 weeks
Number of subjects: 93
Study 21247651 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 93
Study 18953197 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 22
Study 18953197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 17006078 — intervention group
Group type: EXPERIMENTAL
Intervention: Low thoracic epidural analgesia (group E)
Number of subjects: 60
Study 17006078 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (group P)
Number of subjects: 60
Study 17006078 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 14577817 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant orthopedics (IO) based on a modified Zurich approach
Number of subjects: 28
Study 14577817 — intervention group
Group type: COMPARATOR
Intervention: Non-infant orthopedics (non-IO)
Number of subjects: 28
Study 14577817 — intervention group
Group type: COMPARATOR
Intervention: Noncleft controls
Number of subjects: 28
Study 10755669 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual psychotherapy in combination with antipsychotic medications
Number of subjects: 0
Study 10755669 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible psychotherapy
Number of subjects: 0
Study 8864420 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (5 micrograms kg-1 h-1)
Number of subjects: 8
Study 8864420 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (10 mg kg-1 h-1)
Number of subjects: 8
Study 8864420 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study 1847977 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (group A)
Number of subjects: 353
Study 1847977 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy and radiotherapy (group B)
Number of subjects: 353
Study 6679507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous labetalol (1-2 mg/kg; mean dose 86.5 mg)
Number of subjects: 13
Study 6679507 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (3-5 mg/kg; mean dose 253.8 mg)
Number of subjects: 13
Study 30893677 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with tuina (A)
Number of subjects: 135
Study 30893677 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (B)
Number of subjects: 135
Study 30893677 — intervention group
Group type: COMPARATOR
Intervention: Control (flunarizine hydrochloride) (C)
Number of subjects: 135
Study 28550019 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-choice items addressing 22 key concepts
Number of subjects: 1114
Study 28550019 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasch analysis
Number of subjects: 1114
Study 26680752 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) training curriculum
Number of subjects: 20
Study 26680752 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 20
Study 23989030 — intervention group
Group type: EXPERIMENTAL
Intervention: Nia exercise (20-60 minutes, three times per week for 12 weeks)
Number of subjects: 41
Study 23989030 — intervention group
Group type: COMPARATOR
Intervention: Usual care (continuing normal activities)
Number of subjects: 41
Study 21288209 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (75 mg)
Number of subjects: 84
Study 21288209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 20158046 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccoadhesive tablets of diltiazem hydrochloride (DZH) using HPMC K4M and Carbopol 934
Number of subjects: 0
Study 20158046 — intervention group
Group type: COMPARATOR
Intervention: Oral tablets of diltiazem hydrochloride
Number of subjects: 0
Study 17941914 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal breast-milk containing bifidobacteria
Number of subjects: 61
Study 17941914 — intervention group
Group type: COMPARATOR
Intervention: Infants of allergic mothers
Number of subjects: 61
Study 17941914 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants of non-allergic mothers
Number of subjects: 61
Study 17941914 — intervention group
Group type: COMPARATOR
Intervention: Breast-milk from allergic mothers
Number of subjects: 61
Study 17941914 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-milk from non-allergic mothers
Number of subjects: 61
Study 15492491 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher adherence to early treatment for JCP
Number of subjects: 501
Study 15492491 — intervention group
Group type: COMPARATOR
Intervention: Low adherence to early treatment for JCP
Number of subjects: 501
Study 11851609 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrelle Continence Tampon (CCT)
Number of subjects: 94
Study 11851609 — intervention group
Group type: COMPARATOR
Intervention: Conveen Continence Guard (CCG)
Number of subjects: 94
Study 11851609 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices (CCT and CCG)
Number of subjects: 94
Study 9750978 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited symptom attacks (LSA)
Number of subjects: 0
Study 9750978 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent panic (IP)
Number of subjects: 0
Study 9750978 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic disorder (PD)
Number of subjects: 0
Study 9750978 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 9001779 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone (Group G)
Number of subjects: 43
Study 9001779 — intervention group
Group type: COMPARATOR
Intervention: Buserelin (Group B)
Number of subjects: 43
Study 2248838 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 60
Study 2248838 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 7029276 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol (doses that reduced heart rate by 25%)
Number of subjects: 74
Study 7029276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 29619796 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT-CHO
Number of subjects: 20
Study 29619796 — intervention group
Group type: COMPARATOR
Intervention: SIT-Fast
Number of subjects: 20
Study 28814086 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma nesfatin 1 level in patients with first attack psychosis
Number of subjects: 32
Study 28814086 — intervention group
Group type: COMPARATOR
Intervention: Plasma nesfatin 1 level in healthy control group
Number of subjects: 32
Study 28814086 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between plasma nesfatin 1 levels and total PANNS scores in the patient group
Number of subjects: 32
Study 26886327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor standard release (SF) 750 mg
Number of subjects: 12
Study 26886327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor modified release form (MRF) 750 mg
Number of subjects: 12
Study 24807748 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind access for PCNL using lumbar notch landmark
Number of subjects: 100
Study 24807748 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided access for PCNL
Number of subjects: 100
Study 23074432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive counselling or a combination of intensive counselling and nicotine replacement therapy (NRT)
Number of subjects: 8291
Study 23074432 — intervention group
Group type: COMPARATOR
Intervention: Nicotine replacement therapy (NRT)
Number of subjects: 8291
Study 23074432 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant bupropion
Number of subjects: 8291
Study 20605876 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 40
Study 20605876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Number of subjects: 40
Study 18049324 — intervention group
Group type: EXPERIMENTAL
Intervention: Music group (n=54)
Number of subjects: 108
Study 18049324 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=54)
Number of subjects: 108
Study 16130056 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-guided ultrasound (NGU)
Number of subjects: 429
Study 16130056 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound without a needle guide
Number of subjects: 429
Study 11966747 — intervention group
Group type: EXPERIMENTAL
Intervention: SDACTH (250 microg ACTH)
Number of subjects: 51
Study 11966747 — intervention group
Group type: EXPERIMENTAL
Intervention: LDACTH (1 microg ACTH)
Number of subjects: 51
Study 11966747 — intervention group
Group type: COMPARATOR
Intervention: OMT (overnight metyrapone test)
Number of subjects: 51
Study 9863502 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone 50 mg daily
Number of subjects: 0
Study 9863502 — intervention group
Group type: COMPARATOR
Intervention: Fansidar one tablet weekly
Number of subjects: 0
Study 7525635 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute renal failure patients (n = 10)
Number of subjects: 20
Study 7525635 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic renal failure patients (n = 10)
Number of subjects: 20
Study 7525635 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal failure patients (both ARF and chronic)
Number of subjects: 20
Study 7525635 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 20
Study 7525635 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal failure patients
Number of subjects: 20
Study 7525635 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal failure urine samples
Number of subjects: 20
Study 3301926 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical minoxidil (2% or 3%)
Number of subjects: 10
Study 3301926 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of topical minoxidil
Number of subjects: 10
Study 29435588 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A PCV
Number of subjects: 61
Study 29435588 — intervention group
Group type: EXPERIMENTAL
Intervention: Type B PCV
Number of subjects: 61
Study 29435588 — intervention group
Group type: EXPERIMENTAL
Intervention: Type C PCV
Number of subjects: 61
Study 26878376 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash incentives group ($150 for confirmed smoking cessation)
Number of subjects: 114
Study 26878376 — intervention group
Group type: COMPARATOR
Intervention: No incentive group
Number of subjects: 114
Study 24417563 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-implant defect reconstruction with porous titanium granules
Number of subjects: 32
Study 24417563 — intervention group
Group type: COMPARATOR
Intervention: Peri-implant defect reconstruction without porous titanium granules (Control)
Number of subjects: 32
Study 24417563 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (irrespective of treatment allocation)
Number of subjects: 32
Study 20484099 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg before the intervention and 200 mg twice daily for 6 months)
Number of subjects: 271
Study 20484099 — intervention group
Group type: COMPARATOR
Intervention: Control (no celecoxib)
Number of subjects: 271
Study 18777489 — intervention group
Group type: EXPERIMENTAL
Intervention: Muraglitazar 5 mg plus metformin
Number of subjects: 1805
Study 18777489 — intervention group
Group type: EXPERIMENTAL
Intervention: Muraglitazar 2.5 mg plus metformin
Number of subjects: 1805
Study 18777489 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 1 mg
Number of subjects: 1805
Study 16454155 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (Aclasta®), 5 mg infusion
Number of subjects: 357
Study 16454155 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (Actonel®), 30 mg/d orally for 2 months
Number of subjects: 357
Study 16454155 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 357
Study 12441588 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized observations by 3 physical therapists and 2 occupational therapists
Number of subjects: 4
Study 10349786 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulceral (study formula)
Number of subjects: 24
Study 10349786 — intervention group
Group type: COMPARATOR
Intervention: Losec (reference standard formula)
Number of subjects: 24
Study 7813338 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor repair alone
Number of subjects: 0
Study 7813338 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor repair with adjuvant internal anal sphincter plication
Number of subjects: 0
Study 1998019 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl prednisolone (16 mg in 40 cc saline, concentration 40 mg%)
Number of subjects: 76
Study 1998019 — intervention group
Group type: COMPARATOR
Intervention: Gel-saline double-lumen implant with 40 cc saline
Number of subjects: 76
Study 6359384 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin (375 mg, three times daily for 7 days)
Number of subjects: 139
Study 6359384 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (250 mg, three times daily for 7 days)
Number of subjects: 139
Study 31448789 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin/tazobactam (TZP) 300 mg/kg/day after an initial loading dose of 75 mg/kg over 30 min.
Number of subjects: 176
Study 31448789 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion of piperacillin/tazobactam (TZP) 300 mg/kg/day divided into four doses, not exceeding 16 g/day.
Number of subjects: 176
Study 30297911 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant ipilimumab 3 mg kg−1 and nivolumab 1 mg kg−1
Number of subjects: 20
Study 30297911 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant ipilimumab 3 mg kg−1 and nivolumab 1 mg kg−1
Number of subjects: 20
Study 27405968 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET)
Number of subjects: 19
Study 27405968 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 19
Study 24513442 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal lifestyle advice (lifestyle advice)
Number of subjects: 2212
Study 24513442 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2212
Study 22036045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory group
Number of subjects: 130